International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01)

STATUS

Recruiting
End date

Dec 17, 2032
participants needed

700
sponsor

University of Birmingham

Send

Updated on 26 January 2022

See if I qualify

remission

fludarabine

cyclophosphamide

busulfan

cytarabine

flow cytometry

ejection fraction

myeloablative conditioning

gilbert's syndrome

induction chemotherapy

minimal residual disease

daunorubicin

residual tumor

mitoxantrone

idarubicin

ara-c

neoadjuvant therapy

gemtuzumab

blast cells

anthracyclines

Summary

The main purpose of this study is :

To establish which number of doses of gemtuzumab ozogamicin (up to a maximum of 3 doses) is tolerated and can be safety delivered in combination with cytarabine plus mitoxantrone or liposomal daunorubicin in induction
To compare mitoxantrone (anthracenedione) & cytarabine with liposomal daunorubicin (anthracycline) & cytarabine as induction therapy. (Randomisation 1 (R1) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug.)
To compare a single dose of gemtuzumab ozogamicin with the optimum tolerated number of doses of gemtuzumab ozogamicin (identified by the dose-finding study) when combined with induction chemotherapy.
To compare two consolidation regimens: high dose cytarabine (HD Ara-C) and fludarabine & cytarabine (FLA) in standard risk patients.
To compare the toxicity and effectiveness of two haemopoietic stem cell transplant (HSCT) conditioning regimens of different intensity: conventional myeloablative conditioning (MAC) with busulfan/cyclophosphamide and reduced intensity conditioning (RIC) with fludarabine/busulfan.

Description

MyeChild 01 is an international phase III clinical trial in children with acute myeloid leukaemia (AML) a disease with significant mortality. It will compare two induction chemotherapy regimens: mitoxantrone and cytarabine (current standard treatment) with liposomal daunorubicin and cytarabine. This will test liposomal daunorubicin, which is believed to be less cardiotoxic than similar conventional drugs, although this is unproven. (Randomisation 1 (R1) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug.)

Patients responding well to induction chemotherapy are eligible for a randomisation of two consolidation regimens: high dose cytarabine (current standard treatment) or fludarabine and cytarabine (FLA) a regimen commonly used in patients with relapsed disease, testing whether FLA is more effective in front line therapy than standard consolidation treatment. Patients with cytogenetic features associated with a higher risk of relapse and those responding sub-optimally to induction treatment are candidates for haemopoietic stem cell transplant (HSCT) and are eligible for a randomisation comparing two HSCT conditioning regimens: myeloablative conditioning (MAC) (current UNited Kingdom (UK) standard) or reduced intensity conditioning (RIC). HSCT has not consistently shown benefit in high risk patients because the mortality associated with the procedure has outweighed the advantage from a reduction in relapse risk. This will test whether reducing the intensity of conditioning improves survival by reducing transplant related deaths without increasing the relapse rate. The trial incorporates a dose finding study for gemtuzumab ozogamicin. The aim is to identify the optimum tolerated number of doses of gemtuzumab ozogamicin (up to a total of 3 doses), which can be safely combined with either of the induction chemotherapy regimens and then to compare this number of doses with one dose of gemtuzumab ozogamicin. The intensity of treatment will be directed by cytogenetics/molecular genetics and response assessed by minimal residual disease (MRD) levels measured by flow cytometry and molecular methodology.

Details

Condition	Acute Myeloid Leukaemia
Treatment	cyclophosphamide, cytarabine, busulfan, Fludarabine, Mitoxantrone, gemtuzumab ozogamicin, Liposomal daunorubicin
Clinical Study Identifier	NCT02724163
Sponsor	University of Birmingham
Last Modified on	26 January 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Inclusion criteria for trial entry
	Diagnosis of acute myeloid leukaemia (AML) /high risk Myelodysplastic syndrome (MDS) (>10% blasts in the bone marrow)/isolated myeloid sarcoma (MS) (either de novo or secondary)
	Age <18 years at trial entry
	No prior chemotherapy or biological therapy for AML/high risk MDS/isolated MS other than that permitted in the protocol
	Normal cardiac function defined as fractional shortening 28% or ejection fraction 55%
	Fit for protocol chemotherapy
	Documented negative pregnancy test for female patients of childbearing potential
	Patient agrees to use effective contraception (patients of child bearing potential)
	Written informed consent from the patient and/or parent/legal guardian
	Inclusion criteria for participation in the gemtuzumab ozogamicin dose finding
	study
	Centres must be formally activated in order to be take part in the embedded
	dose escalation study. Please contact the trial office for further
	information
	Patient meets the inclusion criteria for trial entry
	Age
	months for the major dose finding study
	weeks and <12 months for the minor dose finding study
	Normal renal function defined as calculated creatinine clearance 90ml/min/1.73m2
	Normal hepatic function defined as total bilirubin 2.5 upper limit of normal (ULN) for age unless it is caused by leukaemic involvement or Gilbert's syndrome or similar disorder
	Alanine transaminase (ALT) or aspartate transaminase (AST) 10 x ULN for age
	Written informed consent from the patient and/or parent/legal guardian
	Inclusion criteria for treatment with gemtuzumab ozogamicin for patients not
	participating in the gemtuzumab ozogamicin dose finding study or R2
	Patient meets the inclusion criteria for trial entry
	Patient meets the inclusion criteria for trial entry (section 4.1.1)
	Age
	months
	Normal renal function defined as calculated creatinine clearance 90ml/min/1.73m2
	weeks
	Normal hepatic function defined as total bilirubin 2.5 ULN for age and not due to leukaemic involvement or Gilbert's syndrome or similar disorder
	days and <12 weeks (patients will receive a maximum of one dose of gemtuzumab ozogamicin)
	ALT or AST 10 x ULN for age
	Normal renal function, defined as calculated creatinine clearance 90 ml/min/1.73m2
	Normal hepatic function, defined as total bilirubin 2.5 upper limit of normal (ULN) for age and not due to leukaemic involvement or Gilbert's syndrome or similar disorder
	Written informed consent from the patient and/or parent/legal guardian
	Inclusion criteria for participation in R3
	Patient meets the inclusion criteria for trial entry
	Inclusion criteria for participation in R2.(once open to randomisation in the
	Induction treatment as per MyeChild 01 protocol or treated with 2 courses of mitoxantrone & cytarabine off trial
	applicable age group)
	Minimal residual disease (MRD) response (performed in MyeChild 01 centralised laboratories, see national MyeChild 01 Laboratory Manual)
	Patients with good risk cytogenetics/molecular genetics and a MRD level <0.1% by flow after course 2, or a decrease in transcript levels of >3 logs after course 2 for those with an informative molecular marker, but without an informative marker of sufficient sensitivity for flow MRD monitoring or
	Patient age
	Patients with intermediate risk cytogenetics/molecular genetics with a MRD level <0.1% by flow after course 1 and course 2, or a decrease in transcript levels of >3 logs after course 1 and course 2 for those with an informative molecular marker, but without an informative marker of sufficient sensitivity for flow MRD monitoring
	months
	Written informed consent from the patient and/or parent/legal guardian
	weeks (once R2 open in patients aged 12 weeks and <12 months)
	Inclusion criteria for participation in R4
	Patient meets the inclusion criteria for trial entry
	Induction treatment as per MyeChild 01 protocol or treated with 1 or 2 courses of mitoxantrone & cytarabine treatment intensification with fludarabine, cytarabine & idarubicin (FLA-Ida) off trial
	ALT or AST 10 x ULN for age
	Patient is in complete remission (CR) or CR with incomplete blood count recovery (CRi) defined as <5% blasts confirmed by flow cytometry/ molecular/FISH in a bone marrow aspirate taken within 6 weeks prior to randomisation to R4
	Patient meets one of the following criteria and is a candidate for HSCT as per the
	protocol
	High risk after course 1 (all patients with poor risk cytogenetics and patients with intermediate risk cytogenetics who fail to achieve CR/CRi)
	Intermediate risk cytogenetics with MRD >0.1% after course 1 and 2 measured by flow. If no flow MRD marker of sufficient sensitivity is identified, a molecular MRD marker with a sensitivity of >0.1% may be used
	Good risk cytogenetics with flow MRD >0.1% confirmed by a decrease in molecular MRD of <3 logs or rising transcript levels after course 3 despite treatment intensification (FLA-Ida) and after discussion with the Clinical Co-ordinators
	Availability of a 9-10/10 human leukocyte antigen (HLA) matched family or unrelated donor or 5-8/8 matched cord blood unit with an adequate cell dose as defined by the protocol section 17.1
	Written informed consent from the patient and/or parent/legal guardian
	Written informed consent from the patient and/or parent/legal guardian
Exclusion Criteria
	Exclusion criteria for all randomisations
	Acute Promyelocytic Leukaemia
	Myeloid Leukaemia of Down Syndrome
	Blast crisis of chronic myeloid leukaemia
	Relapsed or refractory AML
	Bone marrow failure syndromes
	Prior anthracycline exposure which would inhibit the delivery of study anthracyclines
	Pregnant or lactating females
	Concurrent treatment or administration of any other experimental drug or with any other biological therapy for AML/high risk MDS/isolated MS

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Edit Delete

Added by •

•

Private

Edit Delete

Reply by • • Private

Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

Enter the passcode

The passcode will expire in None.

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01)